Amarin (AMRN) in Focus as Traders Await NCE Decision on Vascepa
Tweet
Share
E-mailGet Alerts AMRN Hot Sheet
Join SI Premium – FREE
Amarin (Nasdaq: AMRN) shares are higher on the session as traders anticipate an NCE decision on Vascepa sometime today, though nothing is in stone.
Shares are 24 percent lower from the close on December 6th, with Amarin issuing an update on its plans for Vascepa, covering both MARINE and ANCHOR studies. Many were disappointed that there were mo partnerships or an acquisition announced.
Analysts have been mixed into the decision, some calling Amarin still risky, while others are a little more dovish.
Shares are 1.9 percent higher, having moved back into positive territory just ahead of noon Friday.
Shares are 24 percent lower from the close on December 6th, with Amarin issuing an update on its plans for Vascepa, covering both MARINE and ANCHOR studies. Many were disappointed that there were mo partnerships or an acquisition announced.
Analysts have been mixed into the decision, some calling Amarin still risky, while others are a little more dovish.
Shares are 1.9 percent higher, having moved back into positive territory just ahead of noon Friday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump: nominate Heidi Overton, MD, PhD, as our next FDA commissioner
- Trump on Clarity Act: we need Congress to pass it
- FOMC minutes from July 28-29th meeting
Create E-mail Alert Related Categories
FDA, Momentum Movers, Trader TalkRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
